The relationship between insulin sensitivity and the plasma triglyceride-lowering effect induced byconglycinin was investigated. Male Wistar rats (19 weeks old) were fed diets containing casein, soy protein isolate, or -conglycinin for 4 weeks. In oral glucose administration, the -conglycinin-fed rats showed a significant decrease in the area under the glucose curve (0-60 min) as compared with the casein-fed rats. The hypoglycemic effect was significantly higher in the -conglycinin-fed rats than in the casein-fed rats at 30 min after intraperitoneal insulin injection. The liver sterol regulatory element-binding-protein-1 mRNA expression level was significantly lower and the plasma adiponectin concentration was significantly higher in the -conglycinin-fed rats than in the casein-fed rats. The hypotriglyceridemic effect of -conglycinin depended on a significant decrease in the concentration of very-lowdensity-lipoprotein triglycerides. These results indicate that -conglycinin increases adiponectin levels and improves glucose tolerance. The ability of -conglycinin to lower plasma lipid levels might be due to increased insulin sensitivity of the liver.
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Life style-related diseases such as diabetes and dyslipidemia are serious problems. Many researchers report that impaired glucose disorder mediates between various diseases and obesity. [1] [2] [3] [4] Obesity leads to the production of inflammatory cytokines and induces insulin resistance. 5, 6) Currently, in addition to the development of medical therapies, improvements in life style and exercise are considered important for corpulence patients. 7, 8) Many researchers have shown that caloric restriction and exercise can improve insulin sensitivity. 9) Many dietary nutrients are effective in reducing the risk of disease. The indigestible dextrin is known to be a suppresser of postprandial blood glucose concentration. 10) Soy protein isolate (SPI) has been consumed for a long time and is recognized as having a hypocholesterolemic effect. [11] [12] [13] In a recent report, Nagasawa et al. reported that SPI intake decreased blood glucose in diabetic kk-Ay mice. 14) Recently, Samoto et al. found that 11S globulin (glycinin), lipophilic protein (LP), and 7S globulin (-conglycinin) are the major protein components of SPI. 15) They reported that the ratio of -conglycinin in SPI is 23%. Previous experiments indicated a new physiological function of -conglycinin: consumption of -conglycinin results in a significant decrease in blood triglyceride (TG) concentration in rodents and humans. [16] [17] [18] Although enzymes related to fatty acid metabolism have been shown to be activated byconglycinin, 19) it remains unclear how -conglycinin causes these effects.
In this study, a -conglycinin diet was fed to normal mature rodents, and the regulators of plasma triglyceride concentration were investigated. Measurement of glucose tolerance 20, 21) and mRNA expression in the liver allowed us to identify several key factors involved in the decrease in triglyceride levels caused by -conglycinin.
Materials and Methods
Animals and diets. All animals were treated in accordance with the guidelines established by the Japanese Society for Nutrition and Food Science (Law no. 105 and Notification no. 6 of the Japanese government). Vitamin-free casein (Oriental Yeast, Tokyo), SPI (Fujipro, Fuji Oil, Osaka, Japan), and -conglycinin (Lipoff, Fuji Oil) were provided as dietary proteins. The experimental diets were based on the AIN-93G formula, and are described in Table 1 . 22) Twenty-four specific pathogen-free male Wistar rats, 19 weeks old, were purchased from Japan Crea (Tokyo). All the rats were housed individually in stainless steel cages under controlled conditions (temperature, 23 AE 1 C; humidity, 55 AE 5%; light, 0700-1900 h). After acclimation to commercial food (CRF-1; Oriental Yeast) for 5 d, the rats were divided into three groups with similar average body weights. The experimental diets and water were given ad libitum for 4 weeks. Food intake was recorded daily, and body weight was measured twice a week. Oral glucose tolerance test and insulin tolerance test. An oral glucose tolerance test (OGTT) was done 18 d after the beginning of the experiment. Briefly, each rat was fasted overnight, after which fasting blood samples were collected from the tail vein with a heparinized syringe. Then a 20% glucose solution (2 g of glucose per kg of body weight) was administered orally by sonde, and blood samples were taken at regular time intervals (0, 15, 30, and 60 min). Blood glucose concentrations were measured by Free Style Glucose Sensor (Nipro, Osaka, Japan). Plasma was separated by centrifugation (1;900 Â g, 15 min, 4 C) and stored at 4 C until analysis. Insulin concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Ultra-high Sensitivity Rat Insulin ELISA kit; Morinaga, Yokohama, Japan). The areas under the glucose and insulin curves (the AUCs) were calculated by the trapezoididal rule using the glucose and insulin measurements at 0 (fasting), 15, 30, and 60 min (mg Â min/dl).
An insulin tolerance test (ITT) was performed 7 d after the OGTT. Briefly, each rat was fasted overnight, and fasting blood samples were collected. Insulin (Humulin Ò R; Lilly, Kobe, Japan) was injected intraperitoneally (1 IU of insulin per kg of body weight), and blood samples were collected at 15, 30, and 60 min after injection. Blood glucose concentrations were measured as described above.
Blood analysis. On day 28, after 6 h of food deprivation (0800-1400) blood was withdrawn from the abdominal aorta into a heparinized syringe under isoflurane anesthesia. Plasma was separated by centrifugation and stored at À80 C pending analysis. Plasma leptin (rat leptin ELISA kit; Wako Pure Chemical Industries, Osaka, Japan) and plasma adiponectin (mouse/rat adiponectin ELISA kit; Otsuka Pharmaceutical, Tokyo) levels were measured. After plasma lipoprotein fractions were separated by high-performance liquid chromatography (HPLC), the triglyceride and cholesterol levels in each fraction were analyzed by Skylight-Biotech (Akita, Japan).
23)
Liver lipid analysis. Livers were excised, rinsed, weighed, and then stored at À80 C until further analysis. Liver lipids were extracted by the method of Folch et al., 24) and were analyzed for triglyceride and cholesterol by the methods of Sperry and Webb and Fletcher. 25, 26) Gene expression analysis. Liver and mesenteric adipose tissue samples were dissected from each animal and stored at À80 C for subsequent RNA isolation. Total RNA was isolated using ISOGEN (NipponGene, Tokyo) and purified using an RNeasy spin column and DNase I reagent (Qiagen, Valencia, CA) following the manufacturer's instructions. The total RNA obtained was reversetranscribed into cDNA using the PrimeScriptÔ RT reagent kit (Takara Bio, Tokyo).
Real-time semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed starting with 25 ng of cDNA, along with 50 pM of sense primers and fluorescent-dye-labeled antisense primers (D-LUX SELECT pre-designed primers, Invitrogen, Carlsbad, CA), in an ABI PRISM 7700 sequence detection system (Applied Biosystems Japan, Tokyo). These samples were incubated for initial denaturation at 95 C for 10 min, followed by 40 PCR cycles. Each cycle consisted of 95 C for 30 s, 60 C for 30 s, and 72 C for 20 s. The following rat-gene-specific primers (D-LUX SELECT primer) were used: sterol regulatory element-binding-protein 1 (SREBP1) (Srebf1, RLUX3607120), and fatty acid synthase (FAS) (Fasn, RLUX3604630), apolipoprotein B (ApoB) (Apob, RLUX3604723), with -actin (Actb, RLUX3607934) as housekeeping gene. The specific primers are further described on the Invitrogen website (https://orf.invitrogen.com/lux/LUXSearch.jsp).
Statistical analysis. Data are given as mean AE standard error of the mean (SEM). Statistical analysis was performed by Dr. SPSS (12.0J, SPSS, Tokyo). The results were analyzed by Fisher's Least Significant Difference (LSD) Test (p < 0:05) on the three groups.
Results
Food intake, body weight, and food efficiency ratio Food intake did not differ among the groups (Table 2) . Although body weight in the casein group did not change over the test period, the body weight gain and food efficiency ratio (FER) decreased in the SPI and -conglycinin groups.
Oral glucose tolerance test
The fasting blood glucose levels were 88:8 AE 5:3 mg/dl, 86:2 AE 3:0 mg/dl, and 78:8 AE 2:3 mg/dl in the casein, SPI, and -conglycinin groups respectively. The changes in blood glucose level were smaller in the SPI and -conglycinin groups than in the casein group (Fig. 1A) . At 15 min and 30 min after injection, intake of -conglycinin had significantly suppressed blood glucose elevation compared with casein. The area under the curve (AUC) of blood glucose (0-60 min) was significantly lower in the -conglycinin group and the SPI group than in the casein group (Fig. 1B) . Fasting plasma insulin levels were 1:18 AE 0:24 ng/ml, 1:39 AE 0:27 ng/ml, and 0:97 AE 0:22 ng/ml in the casein, SPI, and -conglycinin groups, respectively. In the casein group, plasma insulin showed a 3.15-fold increase from the initial level at 15 min after glucose administration. On the other hand, plasma insulin levels increased only 2.22-fold in the SPI group and 2.59-fold in theconglycinin group (Fig. 1C) . The AUC of plasma insulin decreased in the following order: casein group > SPI group > -conglycinin group (Fig. 1D ).
Insulin tolerance test Figure 2 shows the rate of decrease in blood glucose concentration. This decrease was more rapid inconglycinin-fed rats than in the casein-fed rats. In the casein group, blood glucose levels had decreased to 70.8% and 57.3% at 15 and 30 min respectively. On the other hand, in the -conglycinin group, blood glucose levels were 56.5% and 46.0% at 15 and 30 min respectively. The blood glucose decrease level was significantly different between the -conglycinin group and the casein group at 15 min after injection.
Analysis of mRNA expression
The gene expression levels of sterol regulatory element-binding protein 1 (SREBP1) mRNA in the liver were significantly lower in the -conglycinin group and the SPI group than in the casein group (Fig. 3A) . The fatty acid synthase (FAS) and apolipoprotein B (Apo B) mRNA expression levels in the -conglycinin 
. Insulin Tolerance Test (ITT).
Time-dependent changes in the blood glucose decrease ratio after intraperitoneal injection of insulin (injection rate, 1 IU of insulin per kg of body weight). The casein group, the SPI group, and theconglycinin group are displayed by circle, square, and triangle respectively. The values of the decrease ratios for each group were calculated by dividing the blood glucose level after insulin injection by the initial blood glucose level. Groups bearing different letters for a given time point are significantly at p < 0:05, by the Fisher LSD test. Values are mean AE SEM (n ¼ 8).
group were slightly lower than in the casein group (Fig. 3B and C) .
Relative liver weights and liver lipid analysis As Table 3 shows relative liver weight was significantly different in the -conglycinin-fed rats as compared with the casein-fed rats. SPI and -conglycinin intake caused a decrease in liver triglyceride level and total cholesterol content as compared with casein intake. Table 4 presents the results of plasma analysis. Plasma leptin was significantly lowered in the - 
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Discussion
This study indicates that -conglycinin, which was obtained by the separation of soy protein, influenced the regulation of plasma glucose. The concentration of blood glucose is strictly regulated by highly complex mechanisms. Secretion of insulin responds quickly to a change in the blood glucose concentration. For instance, the improvement in glucose tolerance caused by cod protein was first found through OGTT. 27) In this study, OGTT and ITT revealed a hypoglycemic effect ofconglycinin. The difference in dietary protein source appeared to alter glucose metabolism through increased insulin sensitivity.
In this study, SPI and -conglycinin significantly decreased SREBP1 mRNA as compared with casein. SREBP1 is known to be a master regulator of de novo fatty acid synthesis.
28) The expression of SREBP1 mRNA is regulated by various signals including liver X receptor (LXR) and insulin. 29, 30) Elevated insulin secretion and LXR activation are involved in the upregulation of SREBP1 in the liver. The fasting insulin level in the -conglycinin-fed rats tended to be lower than that in the casein-fed rats. Though insulin level might influence SREBP1 mRNA expression, the LXR mRNA expression level remained unclear in our research. Further investigation is needed to clarify the effects to SREBP1 regulation caused by -conglycinin.
Adiponectin, which is secreted from mesenteric adipose tissue, plays an important role in glucose metabolism and obesity. 31) Arita et al. reported a strong negative correlation between plasma adiponectin levels and body mass indices. 32) Hotta et al. found that adiponectin levels decreased in non-insulin dependent diabetes mellitus (NIDDM) patients, and pointed out that gluconeogenesis was suppressed by adiponectin in the liver. 33) Nagasawa et al. reported that SPI intake induced adiponectin production.
14) The current study clearly indicates that -conglycinin consumption strongly influences adiponectin levels. Furthermore, -conglycinin causes a significant decrease in the plasma triglyceride concentration via a reduction in the VLDLtriglyceride concentration. -Conglycinin can influence liver triglyceride synthesis and the concentration of VLDL by an increased dose of adiponectin and increased insulin action.
In conclusion, when compared with casein, -conglycinin improved glucose tolerance and insulin sensitivity. A high dose of adiponectin had a hypoglycemic effect and might contribute to reduce the level of insulin. The current investigation indicates thatconglycinin improved insulin resistance by activating crosstalk between the organs responsible for insulin action. Further studies are needed to clarify the influence of -conglycinin in the various tissues.
